Table 5.
Cross tabulation showing changes in uveitis diagnosis before and after work-up.
| Initial clinical uveitis diagnosis | Final infectious (N = 45), % |
Final non- infectious systemic diseases (N = 4), % | Final ocular clinical syndromes (N = 11), % | Final masquerade syndromes (N = 10), % | Final undetermined (N = 16), % | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Toxo (N = 12) | TB (N = 18) | CMV (N = 4) | HSV (N = 2) | Syphilis (N = 3) | Lepra (N = 0) | VZV (N = 2) | Rubella (N = 2) | EBV (N = 2) | |||||
| Infectious (N = 38) | 12/12 (100%) | 14/18 (78%) | 4/4 (100%) | 1/2 (50%) | 2/3 (67%) | 0/0 (0%) | 1/2 (50%) | 1/2 (50%) | 1/2 (50%) | 0/4 (0%) | 2/11 (18%) | 0/10 (0%) | 0/16 (0%) |
| Toxo (N = 17) | 11/12 (91.7%) | 3/18 (16.7%) | 0/4 (0%) | 0/2 (0%) | 1/3 (33.3%) | 0/0 (0%) | 1/2 (50.0%) | 0/2 (0%) | 0/2 (0%) | 0/0 (0%) | 1/2 (50%) | 0/0 (0%) | 0/0 (0%) |
| TB (N = 12) | 0/12 (0%) | 11/18 (16.1%) | 0/4 (0%) | 0/2 (0%) | 0/3 (0%) | 0/0 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/0 (0%) | 1/2 (50%) | 0/0 (0%) | 0/0 (0%) |
| CMV (N = 4) | 1/12 (8.3%) | 0/18 (0%) | 3/4 (75%)∗ | 0/2 (0%) | 0/3 (0%) | 0/0 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/0 (0%) | 0/2 (0%) | 0/0 (0%) | 0/0 (0%) |
| HSV (N = 3) | 0/12 (0%) | 0/18 (0%) | 1/4 (25%) | 1/2 (50%) | 0/3 (0%) | 0/0 (0%) | 0/2 (0%) | 1 (50.0%) | 0/2 (0%) | 0/0 (0%) | 0/2 (0%) | 0/0 (0%) | 0/0 (0%) |
| Syphilis (N = 1) | 0/12 (0%) | 0/18 (0%) | 0/4 (0%) | 0/2 (0%) | 1/3 (33.3%) | 0/0 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/0 (0%) | 0/2 (0%) | 0/0 (0%) | 0/0 (0%) |
| Lepra (N = 1) | 0/12 (0%) | 0/18 (0%) | 0/4 (0%) | 0/2 (0%) | 0/3 (0%) | 0/0 (0%) | 0/2 (0%) | 0/2 (0%) | 1/2 (50.0%) | 0/0 (0%) | 0/2 (0%) | 0/0 (0%) | 0/0 (0%) |
| VZV (N = 0) | 0/12 (0%) | 0/18 (0%) | 0/4 (0%) | 0/2 (0%) | 0/3 (0%) | 0/0 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/0 (0%) | 0/2 (0%) | 0/0 (0%) | 0/0 (0%) |
| Rubella (N = 0) | 0/12 (0%) | 0/18 (0%) | 0/4 (0%) | 0/2 (0%) | 0/3 (0%) | 0/0 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/0 (0%) | 0/2 (0%) | 0/0 (0%) | 0/0 (0%) |
| EBV (N = 0) | 0/12 (0%) | 0/18 (0%) | 0/4 (0%) | 0/2 (0%) | 0/3 (0%) | 0/0 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/0 (0%) | 0/2 (0%) | 0/0 (0%) | 0/0 (0%) |
| Associated with non- infectious systemic diseases (N = 6) | 0/12 (0%) | 0/18 (0%) | 0/4 (0%) | 0/2 (0%) | 1/3 (33%) | 0/0 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 4/4 (100%) | 0/11 (0%) | 1/10 (10%) | 0/16 (0%) |
| Ocular clinical syndromes (N = 10) | 0/12 (0%) | 0/18 (0%) | 0/4 (0%) | 0/2 (0%) | 0/3 (0%) | 0/0 (0%) | 0/2 (0%) | 1/2 (50%) | 0/2 (0%) | 0/4 (0%) | 9/11 (82%) | 0/10 (0%) | 0/16 (0%) |
| Masquerade syndromes (N = 11) | 0/12 (0%) | 0/18 (0%) | 0/4 (0%) | 0/2 (0%) | 0/3 (0%) | 0/0 (0%) | 1/2 (50%) | 0/2 (0%) | 1/2 (50%) | 0/4 (0%) | 0/11 (0%) | 9/10 (90%) | 0/16 (0%) |
| Undetermined (N = 21) | 0/12 (0%) | 4/18 (22%) | 0/4 (0%) | 1/2 (50%) | 0/3 (0%) | 0/0 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/4 (0%) | 0/11 (0%) | 0/10 (0%) | 16/16 (100%) |
∗
One of the patients was diagnosed as syphilis and CMV.